Candesartan cilexetil in children with hypertension or proteinuria: Preliminary data

Giacomo D. Simonetti, Rodo O. Vigier, Martin Konrad, Mattia Rizzi, Emilio Fossali, Mario G. Bianchetti

Research output: Contribution to journalArticlepeer-review


The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood. We were impressed by the neutral taste and the small size of the candesartan cilexetil tablets. This angiotensin II receptor blocker was used during 4 months in 17 pediatric patients (aged 0.5-16, median 4.5 years) with chronic arterial hypertension (n=6), overt proteinuria (n=2), or both (n=9). The initial candesartan dose of 0.23 (0.16-0.28) mg/kg body weight once daily (median and interquartile ranged) was doubled in ten patients [final dose 0.35 (0.22-0.47) mg/kg body weight]. No adverse clinical experiences were noted on candesartan. Candesartan increased plasma potassium by 0.3 (0.0-0.8) mmol/l (P

Original languageEnglish
Pages (from-to)1480-1482
Number of pages3
JournalPediatric Nephrology
Issue number10
Publication statusPublished - Oct 2006


  • Candesartan
  • Child
  • Hypertension
  • Proteinuria

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Candesartan cilexetil in children with hypertension or proteinuria: Preliminary data'. Together they form a unique fingerprint.

Cite this